Residency · Residency · Gastroenterology

Liver Transplantation - Indications and Post-Transplant Care

Indications

Acute Liver Failure

Acute liver failure represents the most urgent indication for liver transplantation and is designated as UNOS Status 1A, the highest priority classification. Patients in this category have an expected survival of less than 7 days without transplantation. The decision to list is guided by King's College Criteria or by clinical assessment that medical management is futile. Common etiologies requiring emergent transplantation include acetaminophen overdose refractory to NAC, viral hepatitis, Wilson disease, drug reactions, and indeterminate causes.

Decompensated Cirrhosis

Decompensated cirrhosis is the most common overall indication for liver transplantation. Referral for transplant evaluation should be initiated when the MELD-Na score reaches 15 or greater, as this threshold represents the point at which the survival benefit of transplantation exceeds waitlist mortality. The MELD 3.0 formula, adopted by UNOS in 2022, incorporates sex and albumin alongside bilirubin, INR, creatinine, and sodium, providing more equitable allocation.

Specific complications that should prompt transplant evaluation include refractory ascites unresponsive to maximal diuretic therapy, recurrent variceal hemorrhage despite optimal endoscopic and pharmacologic management, recurrent or refractory hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome (when PaO2 falls below 60 mmHg), and portopulmonary hypertension (when mean pulmonary arterial pressure exceeds 35 mmHg but remains below 45 mmHg and is amenable to treatment).

Hepatocellular Carcinoma

Patients with hepatocellular carcinoma within Milan criteria receive standardized MELD exception points (MMaT-3, the median MELD at transplant minus 3 in the region) beginning after 6 months of waitlist time. This ensures equitable access for patients whose liver function (and thus calculated MELD) may not reflect their waitlist mortality risk. Patients beyond Milan criteria who achieve successful downstaging through locoregional therapy may be listed for transplantation after demonstrating treatment response. AFP levels exceeding 1000 ng/mL are associated with high recurrence and serve as an exclusionary criterion at some centers.

MELD Exception Points

Standard MELD exceptions are granted for conditions in which the calculated MELD score does not accurately reflect the patient's true waitlist mortality. These include hepatocellular carcinoma within Milan criteria, hepatopulmonary syndrome with PaO2 below 60 mmHg, familial amyloid polyneuropathy, primary hyperoxaluria, severe polycystic liver disease, hilar cholangiocarcinoma meeting select protocol criteria, and recurrent cholangitis in primary sclerosing cholangitis when the MELD may underestimate illness severity.

Disease-Specific Considerations

MASLD and MASH have become the leading or co-leading indication for liver transplantation. Cardiovascular assessment is particularly critical in this population, requiring echocardiography, stress testing, and cardiac catheterization when risk factors are present. Alcoholic liver disease traditionally required 6 months of documented sobriety, though early transplantation for severe alcohol-associated hepatitis is increasingly accepted in carefully selected patients. Hepatitis C should ideally be treated with direct-acting antivirals before transplantation when feasible, though post-transplant treatment is also highly effective. Hepatitis B achieves excellent post-transplant outcomes with hepatitis B immune globulin combined with nucleos(t)ide analogue prophylaxis. Primary sclerosing cholangitis has excellent transplant outcomes, with recurrence in 20 to 25% at 10 years, and select perihilar cholangiocarcinoma protocols using neoadjuvant chemoradiation followed by transplantation are available.

Contraindications

Absolute

Absolute contraindications to liver transplantation include uncontrolled extrahepatic malignancy, severe cardiopulmonary disease that cannot be corrected, active uncontrolled sepsis outside the liver, irreversible brain injury, uncontrolled psychiatric illness preventing compliance with the post-transplant regimen, anatomic abnormalities precluding the transplant operation, and portopulmonary hypertension with mean pulmonary arterial pressure exceeding 45 mmHg that is irreversible despite treatment.

Relative (Evolving)

Relative contraindications are evolving as transplant experience broadens. Advanced age over 70 years is considered in the context of physiologic rather than chronologic age. BMI exceeding 40 is associated with higher perioperative morbidity, though bariatric surgery may be considered simultaneously or before transplantation. HIV infection, when well controlled on antiretroviral therapy, is acceptable, with outcomes similar to HIV-negative recipients. Active substance use requires individualized assessment with addiction medicine involvement. Prior malignancy necessitates an appropriate disease-free interval.

Pre-Transplant Evaluation

Medical Assessment

Cardiovascular evaluation is the most critical component of the pre-transplant workup, as coronary artery disease is the leading cause of perioperative mortality. All patients require echocardiography. Stress testing with dobutamine stress echocardiography or nuclear imaging is indicated for patients over age 50 or those with cardiovascular risk factors. Cardiac catheterization is performed when non-invasive testing is abnormal.

Pulmonary assessment includes pulmonary function tests and arterial blood gas analysis with calculation of the alveolar-arterial oxygen gradient to screen for hepatopulmonary syndrome. Contrast-enhanced echocardiography with agitated saline (bubble study) detects intrapulmonary shunts, and right heart catheterization is performed when portopulmonary hypertension is suspected. The portopulmonary hypertension thresholds are: mean pulmonary arterial pressure below 35 mmHg allows transplantation to proceed, 35 to 45 mmHg requires treatment and reassessment, and above 45 mmHg constitutes a contraindication.

Renal assessment evaluates estimated glomerular filtration rate trends and distinguishes hepatorenal syndrome from intrinsic chronic kidney disease. Simultaneous liver-kidney transplantation is indicated when the patient has been on dialysis for more than 90 days or when the eGFR has remained below 30 for more than 90 days.

Malignancy screening follows age-appropriate cancer screening guidelines and includes CT of the chest and abdomen and colonoscopy. Infectious disease evaluation includes serologies for hepatitis viruses, HIV, cytomegalovirus, Epstein-Barr virus, tuberculosis screening with interferon-gamma release assay or tuberculin skin testing, and screening for syphilis, strongyloides, Chagas disease, and coccidioidomycosis in endemic areas.

Nutritional and frailty assessment is increasingly recognized as a critical determinant of transplant outcomes. Sarcopenia is assessed through hand grip strength, the chair stand test, and CT-based skeletal muscle index measurement. BMI evaluation, dietitian consultation, and branched-chain amino acid supplementation form part of the nutritional optimization strategy.

Psychosocial Assessment

The psychosocial evaluation encompasses social work evaluation, psychiatric assessment addressing depression, anxiety, and coping mechanisms, and substance use assessment conducted by addiction medicine specialists with supervised abstinence verification using biomarkers including phosphatidylethanol, ethyl glucuronide, ethyl sulfate, and urine drug screening. The support system is evaluated with identification of a primary caregiver, assessment of transportation, financial stability, and prediction of medication compliance. All transplant centers employ a multidisciplinary selection committee to make final listing decisions.

<image>A pre-transplant evaluation overview diagram displayed as a systematic checklist organized by organ system. Central liver icon with radiating pathways to each assessment category. (1) "Cardiovascular" (heart icon): echocardiogram, stress testing (dobutamine echo or nuclear), coronary angiography if abnormal, assess for coronary artery disease. (2) "Pulmonary" (lung icon): PFTs, ABG with A-a gradient calculation, contrast echo with bubble study for hepatopulmonary syndrome, right heart catheterization for portopulmonary hypertension (MPAP thresholds: <35 = proceed, 35-45 = treat and reassess, >45 = contraindication). (3) "Renal" (kidney icon): eGFR trend, assess for HRS vs intrinsic CKD, SLK criteria (dialysis >90 days or eGFR <30 for >90 days). (4) "Infectious Disease" (shield icon): HIV, HBV, HCV, CMV, EBV, TB/IGRA, vaccines (live vaccines before transplant), dental clearance. (5) "Malignancy" (ribbon icon): age-appropriate cancer screening, CT chest/abdomen, colonoscopy. (6) "Nutrition/Frailty" (muscle icon): sarcopenia assessment (hand grip, chair stand, CT skeletal muscle index), BMI, dietitian evaluation. (7) "Psychosocial" (brain icon): addiction medicine, psychiatric evaluation, social work, caregiver/support assessment. Use organ-system colors and include pass/fail criteria where applicable.</image>

Organ Allocation

MELD 3.0 (UNOS 2022)

The MELD 3.0 formula incorporates bilirubin, INR, creatinine, sodium, albumin, and sex (with female sex receiving additional points to address the prior allocation disparity). The score is continuous, with higher values indicating higher priority. It is rescored periodically while on the waitlist. Allocation follows ABO blood type compatibility with size matching for pediatric candidates. Regional sharing through broadened acuity circles has been implemented to reduce geographic disparity in organ access.

Donor Types

Deceased donor liver transplantation includes organs from brain death donors and donation after circulatory death. DCD grafts carry an increased risk of ischemic cholangiopathy in 10 to 15% of recipients, though normothermic regional perfusion and ex-vivo machine perfusion technologies are substantially reducing this risk. Living donor liver transplantation, using right lobe hepatectomy for adult-to-adult donation or left lateral segment for adult-to-child donation, expands the donor pool. Critical donor risk assessment is mandatory, as donor mortality for right lobe donation is 0.1 to 0.5%.

Machine perfusion technology, encompassing both hypothermic machine perfusion and normothermic machine perfusion, represents a transformative advance in the field. These technologies allow objective assessment and resuscitation of donor organs before implantation, expanding the usable donor pool by salvaging marginal grafts that would otherwise be discarded and reducing ischemia-reperfusion injury.

Immunosuppression

Induction

Basiliximab is an anti-IL-2 receptor (CD25) monoclonal antibody administered as 20 mg intravenously on days 0 and 4 after transplantation. Its primary advantage is allowing delayed introduction of calcineurin inhibitors, thereby providing renal sparing during the immediate post-transplant period when kidney function is most vulnerable. Thymoglobulin (rabbit antithymocyte globulin) is a more potent polyclonal anti-T cell antibody used in high-immunologic-risk settings or ABO-incompatible transplants, though it carries a higher risk of infectious complications.

Maintenance Regimen (Standard Triple Therapy)

Tacrolimus is the preferred calcineurin inhibitor and the cornerstone of maintenance immunosuppression after liver transplantation, having largely replaced cyclosporine. Target trough levels are 8 to 12 ng/mL in the early post-transplant period, 5 to 8 ng/mL after 6 months, and 3 to 5 ng/mL after 1 year in stable, low-risk patients. The side effect profile of tacrolimus includes nephrotoxicity (the leading cause of chronic renal insufficiency post-transplant), neurotoxicity (tremor, headache, and seizure), new-onset diabetes after transplant (NODAT, occurring in 15 to 30%), hyperkalemia, hypomagnesemia, and alopecia.

Mycophenolate mofetil at 1 to 1.5 grams twice daily inhibits inosine monophosphate dehydrogenase and serves as an antiproliferative agent. Common side effects include gastrointestinal intolerance (nausea and diarrhea) and cytopenias. It is teratogenic and requires careful counseling in women of reproductive age.

Corticosteroids are tapered and weaned over 3 to 12 months, with many centers achieving steroid-free maintenance by 3 to 6 months. An exception is made for autoimmune hepatitis recipients, who may require long-term low-dose corticosteroids to prevent disease recurrence.

CNI-Sparing Strategies

mTOR inhibitors including everolimus and sirolimus allow reduction of calcineurin inhibitor doses, which is particularly important for renal protection. These agents also possess antineoplastic properties that may reduce hepatocellular carcinoma recurrence after transplantation. Side effects include proteinuria, hyperlipidemia, impaired wound healing, mouth ulcers, and cytopenias. mTOR inhibitors must be avoided in the early post-transplant period due to the risks of impaired wound healing and hepatic artery thrombosis.

Rejection Monitoring

Acute cellular rejection occurs in 15 to 25% of liver transplant recipients and presents with elevated aminotransferases, fever, and malaise. Diagnosis requires liver biopsy, which is graded according to the Banff criteria evaluating portal inflammation, bile duct damage, and venous endotheliitis (rejection activity index score 0 to 9). Treatment consists of high-dose intravenous methylprednisolone at 500 to 1000 mg daily for 3 days. Steroid-resistant rejection is treated with thymoglobulin.

Chronic rejection (ductopenic rejection) is rare, occurring in fewer than 5% of recipients, and is characterized by progressive bile duct loss. It may ultimately require retransplantation. Antibody-mediated rejection is increasingly recognized and diagnosed through C4d staining on biopsy in combination with detection of donor-specific antibodies in the serum. Treatment includes plasmapheresis, intravenous immunoglobulin, and rituximab.

Post-Transplant Complications

Early (<30 Days)

Primary graft nonfunction, occurring in 2 to 5% of transplants, represents complete failure of the allograft to function and requires emergent retransplantation. Hepatic artery thrombosis occurs in 3 to 5% and is a surgical emergency that leads to ischemic cholangiopathy and frequently necessitates retransplantation. Doppler ultrasound screening is performed routinely in the early post-transplant period. Portal vein thrombosis occurs in 1 to 2% and is managed with anticoagulation or surgical revision.

Biliary complications are the most common technical complication, affecting 10 to 30% of recipients. Anastomotic leaks occur early, while strictures may develop early or late. ERCP is the first-line intervention for duct-to-duct anastomotic complications, while percutaneous or surgical approaches are used for Roux-en-Y biliary reconstructions. Early infections are predominantly bacterial; cytomegalovirus infection typically occurs at 1 to 3 months; and Pneumocystis and fungal infections require prophylaxis.

Late (>30 Days)

Biliary strictures are classified as anastomotic (localized, typically responsive to ERCP dilation and stenting) or non-anastomotic/ischemic (diffuse intrahepatic involvement, often resulting from hepatic artery thrombosis or DCD donation, and may require retransplantation).

Cytomegalovirus is the most common opportunistic infection after liver transplantation. The highest risk combination is donor-positive/recipient-negative (D+/R-). Prophylaxis with valganciclovir for 3 to 6 months or a preemptive monitoring strategy with treatment initiated upon viral detection are both accepted approaches.

Recurrent disease in the allograft follows predictable patterns for each primary liver disease. Hepatitis C recurrence is universal without treatment, but direct-acting antivirals achieve sustained virologic response in more than 95% of post-transplant patients. Hepatitis B recurrence is effectively prevented with hepatitis B immune globulin combined with nucleos(t)ide analogue therapy. Autoimmune hepatitis recurs in 20 to 40%, primary sclerosing cholangitis in 20 to 25% at 10 years, and MASLD/MASH commonly recurs in the setting of ongoing metabolic syndrome. Hepatocellular carcinoma recurs in 10 to 20%.

De novo malignancy occurs at 2 to 3 times the rate of the general population due to chronic immunosuppression. Post-transplant lymphoproliferative disorder, driven by Epstein-Barr virus particularly in the D+/R- combination, is managed by reducing immunosuppression and administering rituximab. Skin cancer, with squamous cell carcinoma more common than basal cell carcinoma, requires annual dermatologic screening. Solid organ cancers also occur at increased rates.

Renal dysfunction from chronic calcineurin inhibitor nephrotoxicity is a major long-term concern, with 20 to 25% of recipients developing CKD stage 4 to 5 by 10 years. CNI-sparing strategies using mTOR inhibitors and MMF-based regimens are important for renal preservation.

Cardiovascular disease is accelerated by immunosuppression-related diabetes, hypertension, and dyslipidemia, and is the leading cause of late mortality. Metabolic syndrome with weight gain, NODAT, hypertension, and dyslipidemia is common, and MASLD develops in the allograft in 30 to 50% of recipients.

Long-Term Monitoring

Routine Follow-Up

Laboratory monitoring includes liver function tests, tacrolimus trough levels, complete blood count, and comprehensive metabolic panel. The frequency begins weekly in the first month, transitions to biweekly during months 2 to 3, monthly during months 4 to 12, and every 3 to 6 months thereafter. Annual assessments include cardiovascular risk evaluation, hemoglobin A1c, lipid panel, renal function, bone densitometry, age-appropriate cancer screening, dermatologic examination, and ophthalmologic evaluation. Recipients transplanted for hepatocellular carcinoma require AFP measurement and CT or MRI every 6 to 12 months for at least 5 years for recurrence surveillance.

Vaccination

Live vaccines are contraindicated for the duration of immunosuppressive therapy. Recommended vaccines include influenza (annually), COVID-19 (per current recommendations), pneumococcal vaccines, hepatitis A and B (with titer verification), and the recombinant zoster vaccine (Shingrix, which is a non-live vaccine). Childhood vaccination schedules should be completed before transplantation in pediatric patients.

Outcomes

Overall survival at 1 year is 85 to 90%, at 5 years 70 to 75%, and at 10 years 60 to 65%. The best outcomes are observed in primary biliary cholangitis, primary sclerosing cholangitis, biliary atresia, and metabolic liver diseases. Graft half-life is approximately 12 to 15 years for deceased donor grafts and approximately 10 years for DCD grafts, with improvements anticipated from modern immunosuppression protocols and machine perfusion technologies. The leading causes of late mortality are cardiovascular disease, de novo malignancy, infection, renal failure, and recurrent disease.

Key Clinical Pearls

• MELD 3.0 (2022) incorporates sex and albumin for more equitable allocation. Transplant evaluation should be initiated when MELD-Na reaches 15 or greater.
• Cardiovascular disease is the leading cause of perioperative mortality and late post-transplant mortality. Thorough pretransplant cardiac evaluation is essential.
• Tacrolimus is the cornerstone of maintenance immunosuppression, with target troughs decreasing over time from 8 to 12 ng/mL early to 3 to 5 ng/mL in stable long-term patients.
• Biliary complications are the most common technical complication (10 to 30%). ERCP is first-line for duct-to-duct anastomotic strictures.
• CMV D+/R- is the highest risk combination for CMV disease. Valganciclovir prophylaxis for 3 to 6 months or preemptive monitoring strategy is required.
• HCV recurrence post-transplant is universal without treatment, but DAAs achieve SVR in more than 95% of patients. Treatment is typically initiated at 3 to 6 months post-transplant with stable graft function.
• Twenty to 25% of liver transplant recipients develop CKD stage 4 to 5 by 10 years. CNI-sparing strategies including mTOR inhibitors and MMF-based regimens are important for renal preservation.
• Machine perfusion (normothermic and hypothermic) is expanding the donor pool by enabling assessment and resuscitation of marginal grafts.

References

1. Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the AASLD and AST. Hepatology. 2014;59(3):1144-1165.
2. Kim WR, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161(6):1887-1895.
3. Lucey MR, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by AASLD and AST. Liver Transpl. 2013;19(1):3-26.
4. Nasralla D, et al. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50-56.
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64(2):433-485.

Read this lecture as Markdown